Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
about
A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemiaInternational Consensus Document (ICON): Common Variable Immunodeficiency DisordersCosts of Hospital Admission on Primary Immunodeficiency Diseases.Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada.Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy.Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
P2860
Q26766388-879DEEB6-58AD-4D82-A625-30E01ED99E3CQ26777304-91DFBF2A-444D-4A03-A8BE-009750EAA0DFQ33575500-C637A3EE-BF0D-4126-9EA5-FBF7C543AAFDQ33676857-A6E3FCA0-CC71-4128-9038-B691EA470753Q33692418-6BAD3C20-31B5-4DDA-8371-93A76B4D2902Q35827701-52901614-D4B7-4E06-83EC-A59F0C6E8740Q36094658-D225301C-EB83-40C8-9FA0-2762CBCB3773Q38122120-C362960A-CE78-4ECD-8E34-1D5C02B9D4CEQ38152428-622AAEC7-2B7E-4E80-B39D-4530B80A119AQ38266635-45F5D42F-574A-44CB-95D3-EFF34FA5531CQ39799989-F073F0D4-A11D-4BEB-BDB5-5C90C8D528EFQ46042925-BDC26FED-E6A0-4148-9338-0FB26659FD5CQ47217747-73253D8C-EED6-4790-9047-E1886AC7C7B0Q55311044-7B8BD166-3CBA-4D03-9153-1CDC4AA5E3C1Q57612649-77E22B9B-AC51-44B5-BEA5-FC58A4AB1199
P2860
Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Economic benefits of subcutane ...... ith primary immune deficiency.
@en
Economic benefits of subcutane ...... ith primary immune deficiency.
@nl
type
label
Economic benefits of subcutane ...... ith primary immune deficiency.
@en
Economic benefits of subcutane ...... ith primary immune deficiency.
@nl
prefLabel
Economic benefits of subcutane ...... ith primary immune deficiency.
@en
Economic benefits of subcutane ...... ith primary immune deficiency.
@nl
P2093
P2860
P1433
P1476
Economic benefits of subcutane ...... ith primary immune deficiency.
@en
P2093
M Goetghebeur
R Schellenberg
P2860
P356
10.1111/J.1365-3148.2012.01201.X
P577
2012-11-20T00:00:00Z